<DOC>
	<DOCNO>NCT00212108</DOCNO>
	<brief_summary>EGFR COX-2 involved tumorigenesis , angiogenesis metastasis frequently express NPC.COX-2 EGFR inhibitor active NPC.There synergistic action COX-2 EGFR inhibitor . Study hypothesis : Celecoxib gefitinib reduce angiogenesis induce anti-tumorigenicity patient nasopharngeal cancer .</brief_summary>
	<brief_title>A Study Of Nasopharyngeal Carcinoma ( NPC ) Treated With Celecoxib And ZD1839</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Histologically proven NPC . 2 . Any clinical stage NPC define AJCC/UICC System . 3 . No prior radiotherapy , chemoradiotherapy , immunotherapy investigational agent . 4 . No prior NSAIDs corticosteroid least 4 week . 5 . ECOG performance status â‰¤ 2 . 6 . Adequate end organ function 7 . Life expectancy &gt; 3 month . 8 . Signed informed consent 1 . Inability take celecoxib gefitinib specify period time ( 14 day ) prior definitive therapy . 2 . Tumor visible fibre nasopharyngoscopy biopsy . 3 . Known peptic ulcer disease . 4 . Evidence clinically active interstitial lung disease . 5 . Previous concomitant malignancy exception adequately treat carcinomainsitu cervix basal squamous cell carcinoma skin . 6 . Women pregnant lactating . Females childbearing potential must negative serum pregnancy test within 7 day prior study enrolment . 7 . Women childbearing potential practising adequate contraception . 8 . Concurrent medical problem would significantly limit compliance study . 9 . Presence underlie medical condition ( eg . Unstable uncompensated respiratory , cardiac , renal hepatic disease ) opinion investigator would make patient unsuitable study participation . 10 . Known hypersensitivity celecoxib gefitinib excipients product , know sulphonamide sensitivity allergic reaction follow ingestion NSAIDs . 11 . Known HIV , HBV HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>celecoxib , NPC , gefitinib</keyword>
</DOC>